Crystallographic analysis of the N-terminal domain of_              _i_Middle East respiratory syndrome coronavirus

  • 0 0 0
  • Like this paper and download? You can publish your own PDF file online for free in a few minutes! Sign Up

Crystallographic analysis of the N-terminal domain of_ _i_Middle East respiratory syndrome coronavirus

research communications ISSN 2053-230X Crystallographic analysis of the N-terminal domain of Middle East respiratory s

370 106 344KB

Pages 4 Page size 609.675 x 793.701 pts Year 2015

Report DMCA / Copyright

DOWNLOAD FILE

Recommend Papers

File loading please wait...
Citation preview

research communications

ISSN 2053-230X

Crystallographic analysis of the N-terminal domain of Middle East respiratory syndrome coronavirus nucleocapsid protein Yong-Sheng Wang,a,b Chung-ke Changc and Ming-Hon Houa,b* a

Received 18 March 2015 Accepted 26 May 2015 Edited by M. S. Weiss, Helmholtz-Zentrum Berlin fu¨r Materialien und Energie, Germany Keywords: Middle East respiratory syndrome coronavirus; nucleocapsid protein; N-terminal domain; RNA binding. Supporting information: this article has supporting information at journals.iucr.org/f

Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan, bInstitute of Genomics and Bioinformatics, National Chung Hsing University, Taichung 402, Taiwan, and cInstitute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan. *Correspondence e-mail: [email protected]

The N-terminal domain of the nucleocapsid protein from Middle East respiratory syndrome coronavirus (MERS-CoV NP-NTD) contains many positively charged residues and has been identified to be responsible for RNA binding during ribonucleocapsid formation by the virus. In this study, the crystallization and crystallographic analysis of MERS-CoV NP-NTD (amino acids 39–165), with a molecular weight of 14.7 kDa, are reported. MERS-CoV NP-NTD was crystallized at 293 K using PEG 3350 as a precipitant and a 94.5% ˚ complete native data set was collected from a cooled crystal at 77 K to 2.63 A resolution with an overall Rmerge of 9.6%. The crystals were monoclinic and belonged to space group P21, with unit-cell parameters a = 35.60, b = 109.64, ˚ , = 101.22 . The asymmetric unit contained four MERS-CoV NPc = 91.99 A NTD molecules.

1. Introduction

# 2015 International Union of Crystallography

Acta Cryst. (2015). F71, 977–980

Between 2003 and 2004, Severe acute respiratory syndrome coronavirus (SARS-CoV) caused a worldwide epidemic and had a significant economic impact in countries affected by the outbreak (Lai, 2003). In 2004, another alphacoronavirus, Human coronavirus NL63 (HCoV-NL63), was isolated from a seven-month-old child in the Netherlands suffering from bronchiolitis and conjunctivitis (Pyrc et al., 2004). In 2005, Woo and coworkers discovered the novel betacoronavirus Human coronavirus HKU1 in patients with respiratory-tract infections (Woo et al., 2005). Recently, Middle East respiratory syndrome coronavirus (MERS-CoV) has been found in patients with severe acute respiratory-tract infections in the Middle East (Woo et al., 2014). As is the case for all coronaviral infections, there are no efficacious therapies currently available against coronaviral diseases, making the development of anticoronaviral compounds a priority. The virion envelope surrounding the nucleocapsid contains the following structural proteins: S (spike), M (matrix), E (envelope) and N (nucleocapsid). Some of them have a third glycoprotein, HE (haemagglutinin-esterase), which is present in most alphacoronaviruses. The primary function of the HCoV N protein is to recognize a stretch of RNA that serves as a packaging signal and leads to the formation of the ribonucleoprotein (RNP) complex during assembly (Chang et al., 2014). The RNP may be important in keeping the RNA in an ordered conformation suitable for replication and transcription of the viral genome (Lai, 2003; Nelson et al., 2000; Huang et al., 2004; NavasMartı´n & Weiss, 2004). In addition, the N protein has been identified as an important diagnostic marker and the most http://dx.doi.org/10.1107/S2053230X15010146

977

research communications Table 1 Macromolecule-production information. Source organism

Middle East respiratory syndrome coronavirus The templates for the MERS-CoV N protein were provided by AllBio Science Incorporation, Taichung, Taiwan. The primers for the MERS-CoV N protein were provided by Genomics BioSci & Tech Ltd, New Taipei City, Taiwan.

DNA source

Forward primer

CTTATCGCATATGAACACCGTGAGCTGGTATACCGGC CTTACGGCTCGAGGGTGCCTTCAATATGAAAGTTTTTCG

Reverse primer Cloning vector Expression vector Expression host Complete amino-acid sequence of the construct produced

pET-28a (Novagen) pET-28a (Novagen) Escherichia coli BL21 (DE3) pLysS HHHHHHSSGLVPRGSHMNTVSWYTGLTQHGKVPLTFPPGQGVPLNANSTPAQNAGYWRRQDRKINTGNGIKQLAPRWYFYYTGTGPEAALPFRAVKDGIVWVHEDGATDAPSTFGTRNPNNDSAIVTQFAPGTKLPKNFHIEGT

‘immunodominant’ antigen in infected hosts (Chan et al., 2005; Woo et al., 2004; Liang et al., 2013). The N protein of MERS-CoV, with a molecular weight of 45.6 kDa and a pI of 10.05, is highly basic and hydrophilic (Woo et al., 2014). Previous studies revealed that the N-terminal domain of CoV (NP-NTD) contains mostly positively charged residues, which are responsible for RNA binding, while the C-terminal domain (NP-CTD) mainly acts as an oligomerization module to form a capsid (Huang et al., 2009; Saikatendu et al., 2007; Lo et al., 2013; Chen et al., 2013). The central disordered region of the N protein has also been shown to contain an RNA-binding region (Chang et al., 2009). We have shown that compounds that bind to the NP-NTD and interfere with NP–RNA interactions provide valuable leads for the development of anti-coronaviral therapeutics (Lin et al., 2014). The crystal structures of several NP-NTDs,

including those from SARS-CoV, Infectious bronchitis virus (IBV), Human coronavirus OC43 (HCoV-OC43) and Mouse hepatitis virus (MHV), have been described (Chen et al., 2013; Ma et al., 2010; Saikatendu et al., 2007; Jayaram et al., 2006; Yu et al., 2006; Fan et al., 2005). In order to clarify the mechanism by which the N protein of MERS-CoV bind to nucleic acids, we have undertaken the determination of the crystal structure of the N-terminal domain of MERS-CoV spanning residues 39–165, which shares 58% identity to NP-NTD of SARS-CoV. The results presented in this paper mainly concern the crystallization and preliminary X-ray structural analysis of MERSCoV NP-NTD.

2. Materials and methods 2.1. Macromolecule production

The templates for the MERS-CoV N protein were purchased from AllBio Science Incorporated, Taichung, Taiwan. Truncated forms of recombinant MERS-CoV NPNTD were generated by polymerase chain reaction (PCR) of a pGENT plasmid encoding the N-protein gene using different primers. The PCR products were digested with NdeI and XhoI, and the DNA fragments were cloned into pET-28a (Novagen) using T4 ligase (NEB). Expression of the protein was initiated by adding IPTG to a final concentration of 1 mM followed by incubation at 10 C for 24 h. After harvesting the bacteria by centrifugation (8000 rev min1, 12 min, 4 C), the bacterial pellets were resuspended in lysis buffer (50 mM Tris– HCl, 150 mM NaCl, 15 mM imidazole, 1 mM PMSF pH 7.5) and lysed by sonication on ice using 3 s pulses with 6 s pauses for a total of 10 min. Soluble proteins were obtained from the supernatant after centrifugation (13 000 rev min1, 40 min, 4 C). NP-NTD carrying an N-terminal His6 tag fused to a SSGLVPRGSHM linker sequence was purified using an Ni– NTA column (Novagen) and eluted with a buffered imidazole gradient of 15–250 mM. Fractions containing pure protein

Figure 1 SDS–PAGE analysis of MERS-CoV NP-NTD stained with Coomassie Brilliant Blue. Lane M, protein molecular-mass marker (labelled in kDa); lane 1, concentrated MERS-CoV NP-NTD after dialysis; lane 2, purified MERS-CoV NP-NTD.

978

Wang et al.



Figure 2 Crystals of MERS-CoV NP-NTD obtained by the sitting-drop vapourdiffusion method. The largest crystals in the needle clusters are approximately 300  20  10 mm in size.

N-terminal domain of MERS-CoV nucleocapsid protein

Acta Cryst. (2015). F71, 977–980

research communications were collected at 150 mM imidazole and were dialyzed against 50 mM Tris-buffered solution at pH 7.5 containing 150 mM NaCl for 3 h at 4 C (Fig. 1). The purified NP-NTD was further concentrated using Amicon Ultra centrifugal filter units and centrifuged at 3500g for 10 min at 4 C several times until the concentration of NP-NTD reached 10 mg ml1 as determined by the Bradford method (BioShop Canada Inc.). Macromolecule-production information is summarized in Table 1.

Table 2 Crystallization. Method Plate type Temperature (K) Protein concentration (mg ml1) Buffer composition of protein solution Composition of reservoir solution Volume and ratio of drop

2.2. Crystallization

Volume of reservoir (ml)

Initial crystallization conditions were identified by using the sitting-drop vapour-diffusion method with crystal screening kits from Molecular Dimensions as described previously (Till et al., 2013; Chen et al., 2014). Each of the solutions (2 ml) from the crystal screening kits was mixed with 2 ml purified protein solution (10 mg ml1) and allowed to equilibrate against 300 ml solution in the well at room temperature (25 C). The conditions were refined and crystals were grown from a well solution using the sitting-drop vapour-diffusion method by equilibrating a mixture of 2 ml protein solution (10 mg ml1) and 2 ml reservoir solution against 300 ml reservoir solution consisting of 2 mM NaBr, 75 mM ammonium sulfate, 29% PEG 3350 (Sigma). Crystals appeared within two weeks and the largest crystal in the needle clusters grew to dimensions of approximately 300  20  10 mm (Fig. 2). Crystallization information is summarized in Table 2. 2.3. Data collection and processing

X-ray data were collected using synchrotron radiation with a crystal-to-detector distance of 350 mm. The oscillation width and exposure time for each frame were 1 and 20 s, respectively. Crystallographic data integration and reduction were

Vapour diffusion 24-well sitting-drop plate (Hampton Research) 293 10 50 mM Tris–HCl pH 7.5, 75 mM NaCl 2 mM NaBr, 75 mM ammonium sulfate, 29% PEG 3350 1:1; 2 ml reservoir solution was mixed with 2 ml purified protein solution 300

performed with the HKL-2000 program package (Otwinowski & Minor, 1997). The crystallographic data-collection statistics for NP-NTD are listed in Table 3.

3. Results and discussion The MERS-CoV NP-NTD crystal chosen for this study ˚ resolution (Fig. 3) and belonged to space diffracted to 2.63 A group P21, with unit-cell parameters a = 35.60, b = 109.64, ˚ , = 101.22 . The Matthews coefficient of c = 91.99 A 3 1 ˚ calculated using MATTHEWS_COEF from 2.63 A Da CCP4 (Winn et al., 2011; Matthews, 1968) suggested that there were four molecules in an asymmetric unit with a solvent content of 59.2%. A homology search for the MERS-CoV NP-NTD structure was performed using the BLAST server (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The model-selection criterion was based on the E-value and the estimated precision value. The sequence-alignment search indicated that MERSCoV NP-NTD shares high identity with other NP-NTDs from coronaviruses (Supplementary Fig. S1). For example, the MERS-CoV NP-NTD (residues 39–165) has 58% sequence

Figure 3 Typical X-ray diffraction pattern of MERS-CoV NP-NTD. Acta Cryst. (2015). F71, 977–980

Wang et al.



N-terminal domain of MERS-CoV nucleocapsid protein

979

research communications References

Table 3 Data collection and processing. Values in parentheses are for the outer shell. Diffraction source

BL13B1 beamline, National Synchrotron Radiation Research Center (NSRRC), Hsinchu, Taiwan ˚) Wavelength (A 1.000 Temperature (K) 77 Detector ADSC Q315r Crystal-to-detector distance (mm) 350 Rotation range per image ( ) 1 Total rotation range ( ) 360 Exposure time per image (s) 20 Space group P21 ˚) a, b, c (A 35.60, 109.64, 91.99 , , ( ) 90, 101.22, 90 Mosaicity ( ) 1.053 ˚) Resolution range (A 30–2.63 (2.73–2.63) Total No. of reflections 138439 No. of unique reflections 13974 Completeness (%) 94.5 (91.4) Multiplicity 7.1 (5.9) hI/(I)i 18.89 (3.03) Rr.i.m. 0.01 (0.08) Overall B factor from Wilson 43.1 ˚ 2) plot (A

identity to SARS-CoV NP-NTD. The NTD from SARS-CoV (PDB entry 2ofz; Saikatendu et al., 2007) was chosen as the initial model as its E-value was 1  1023, and a total of 116 residues were modelled. The first molecular-replacement trial was performed using the PERON automated interface at the Protein Tectonics Platform (PTP), RIKEN SPring-8 Center, Japan (Sugahara et al., 2008). The core of the model consisted of a tightly packed -sheet surrounded by large loops. The molecular-replacement method was then applied to the model using MOLREP (Vagin & Teplyakov, 2010) using reflections ˚ . Single and unambiguous in the resolution range 8.5–3.0 A solutions for four NP-NTD molecules in one asymmetric unit were obtained in the rotation and translation functions, yielding a final correlation coefficient of 0.81 and an R factor of 0.32. Structural refinement of MERS-CoV NP-NTD is currently in progress.

Acknowledgements This work was supported by the MOST 103-2113-M-005-007MY3. We thank the beamline staff at the BL13B1 beamline, National Synchrotron Radiation Research Center (NSRRC), Hsinchu, Taiwan for assistance. We are also grateful for access to the Protein Tectonics Platform (PTP), which is a structural biology facility collaboration between RIKEN SPring-8 Center, Japan and NSRRC, Taiwan.

980

Wang et al.



Chan, K. H., Cheng, V. C. C., Woo, P. C. Y., Lau, S. K. M., Poon, L. L. M., Guan, Y., Seto, W. H., Yuen, K. Y. & Peiris, J. S. M. (2005). Clin. Diagn. Lab. Immunol. 12, 1317–1321. Chang, C.-K., Hou, M.-H., Chang, C.-F., Hsiao, C.-D. & Huang, T.-H. (2014). Antiviral Res. 103, 39–50. Chang, C.-K., Hsu, Y.-L., Chang, Y.-H., Chao, F.-A., Wu, M.-C., Huang, Y.-S., Hu, C.-K. & Huang, T.-H. (2009). J. Virol. 83, 2255– 2264. Chen, I.-J., Yuann, J.-M. P., Chang, Y.-M., Lin, S.-Y., Zhao, J., Perlman, S., Shen, Y.-Y., Huang, T.-H. & Hou, M.-H. (2013). Biochim. Biophys. Acta, 1834, 1054–1062. Chen, Y.-W., Jhan, C.-R., Neidle, S. & Hou, M.-H. (2014). Angew. Chem. Int. Ed. 53, 10682–10686. Fan, H., Ooi, A., Tan, Y. W., Wang, S., Fang, S., Liu, D. X. & Lescar, J. (2005). Structure, 13, 1859–1868. Huang, C.-Y., Hsu, Y.-L., Chiang, W.-L. & Hou, M.-H. (2009). Protein Sci. 18, 2209–2218. Huang, Q., Yu, L., Petros, A. M., Gunasekera, A., Liu, Z., Xu, N., Hajduk, P., Mack, J., Fesik, S. W. & Olejniczak, E. T. (2004). Biochemistry, 43, 6059–6063. Jayaram, H., Fan, H., Bowman, B. R., Ooi, A., Jayaram, J., Collisson, E. W., Lescar, J. & Prasad, B. V. (2006). J. Virol. 80, 6612–6620. Lai, M. M. C. (2003). J. Biomed. Sci. 10, 664–675. Liang, F.-Y., Lin, L.-C., Ying, T.-H., Yao, C.-W., Tang, T.-K., Chen, Y.-W. & Hou, M. H. (2013). J. Virol. Methods, 187, 413–420. Lin, S.-Y., Liu, C.-L., Chang, Y.-M., Zhao, J., Perlman, S. & Hou, M.-H. (2014). J. Med. Chem. 57, 2247–2257. Lo, Y.-S., Lin, S.-Y., Wang, S.-M., Wang, C.-T., Chiu, Y.-L., Huang, T.-H. & Hou, M.-H. (2013). FEBS Lett. 587, 120–127. Ma, Y., Tong, X., Xu, X., Li, X., Lou, Z. & Rao, Z. (2010). Protein Cell, 1, 688–697. Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. Navas-Martı´n, S. R. & Weiss, S. (2004). J. Neurovirol. 10, 75–85. Nelson, G. W., Stohlman, S. A. & Tahara, S. M. (2000). J. Gen. Virol. 81, 181–188. Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326. Pyrc, K., Jebbink, M. F., Berkhout, B. & van der Hoek, L. (2004). Virol. J. 1, 7. Saikatendu, K. S., Joseph, J. S., Subramanian, V., Neuman, B. W., Buchmeier, M. J., Stevens, R. C. & Kuhn, P. (2007). J. Virol. 81, 3913–3921. Sugahara, M. et al. (2008). J. Struct. Funct. Genomics, 9, 21–28. Till, M., Robson, A., Byrne, M. J., Nair, A. V., Kolek, S. A., Shaw Stewart, P. D. & Race, P. R. (2013). J. Vis. Exp. (78), e50548. Vagin, A. & Teplyakov, A. (2010). Acta Cryst. D66, 22–25. Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242. Woo, P. C. Y. et al. (2005). J. Infect. Dis. 192, 1898–1907. Woo, P. C. Y., Lau, S. K. P., Wernery, U., Wong, E. Y. M., Tsang, A. K. L., Johnson, B., Yip, C. C. Y., Lau, C. C. Y., Sivakumar, S., Cai, J.-P., Fan, R. Y. Y., Chan, K.-H., Mareena, R. & Yuen, K.-Y. (2014). Emerg. Infect. Dis. 20, 560–572. Woo, P. C. Y., Lau, S. K. P., Wong, B. H. L., Chan, K.-H., Hui, W.-T., Kwan, G. S. W., Peiris, J. S. M., Couch, R. B. & Yuen, K.-Y. (2004). J. Clin. Microbiol. 42, 5885–5888. Yu, I.-M., Oldham, M. L., Zhang, J. & Chen, J. (2006). J. Biol. Chem. 281, 17134–17139.

N-terminal domain of MERS-CoV nucleocapsid protein

Acta Cryst. (2015). F71, 977–980